Target intelligence / Profile preview

Streptococcus pneumoniae capsular polysaccharide serotype 19F (CPS19F) (CPS19F)

Target
CPS19F
Molecular classification
Other
01

Overview

Streptococcus pneumoniae capsular polysaccharide serotype 19F is a complex carbohydrate polymer that encapsulates the 19F strain of the pneumococcus bacterium. This polysaccharide acts as a primary virulence factor by providing a physical barrier that prevents host immune cells from performing phagocytosis and inhibits complement deposition (Source: PubMed, PMID: 11514318). Serotype 19F is frequently associated with invasive pneumococcal disease and is a common cause of respiratory infections and meningitis globally (Source: CDC, Pneumococcal Disease). Because of its clinical significance, it is a key antigenic component in both pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs) (Source: WHO, Pneumococcal vaccines). These vaccines trigger the production of protective antibodies that bind to the polysaccharide, allowing the immune system to identify and destroy the bacteria (Source: StatPearls, Pneumococcal Vaccine). Serotype 19F is also notable for its frequent association with multi-drug resistance, making vaccine-mediated prevention a critical public health strategy (Source: PubMed, PMID: 22412062).

Other names
Pneumococcal polysaccharide serotype 19F19F CPSType 19F capsular polysaccharideStreptococcus pneumoniae type 19F antigenSpn CPS 19F
02

Mechanism of action

Induction of serotype-specific opsonophagocytic antibodies that facilitate bacterial recognition and clearance by the host immune system; in conjugate vaccines, the polysaccharide is linked to a carrier protein to elicit a T-cell dependent immune response, which is essential for long-term memory and efficacy in infants (Source: StatPearls, Pneumococcal Vaccine; PubMed, PMID: 24512656).

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Serotype replacementInjection site reactionsHypersensitivityReduced immunogenicity in infants for non-conjugated polysaccharide forms
06

Interacting drugs

Pneumococcal 7-valent Conjugate Vaccine (PCV7)

5 more in the full profile.

07

Biomarkers

Serotype-specific IgG antibody concentrationOpsonophagocytic activity (OPA) titer

Beyond the preview

Go deeper on Streptococcus pneumoniae capsular polysaccharide serotype 19F (CPS19F) (CPS19F).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide serotype 19F (CPS19F) (CPS19F).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call